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Polymorphisms of Coagulation Factor XIII Subunit A and
Risk of Nonfatal Hemorrhagic Stroke in Young White Women
Alexander P Reiner, MD, Stephen M Schwartz, PhD, Michele B Frank, MD,
W T Longstreth, Jr, MD, MPH, Lucia A Hmdorff, BA, Gayle Teramura, BS, Fnts R Rosendaal, MD,
Lakshmi K Gaur, PhD, Bruce M Psaty, MD, PhD, David S Siscovick, MD, MPH
Batkground and Purpose—Although family studies have suggested a genetic mfluence on hemorrhagic stroke, the
underlymg genetic nsk factors remam poorly defmed Coagulation factor XIII, which is mvolved m hemostasis,
fibnnolysis, vascular remodelmg, and tissue repair, represents a candidate gene for hemorrhagic stroke We assessed the
potential role of 3 factor XIII subunit A codmg-sequence polymorphisms, along with a promoter polymorphism of
plasmmogen activator mhibitor-1 (PAI-1, which is also mvolved in fibrin stabilization and vascular remodelmg), m
young white women with hemorrhagic stroke
Methods—Genotype analysis for factor XIII subunit A Val34Leu, Tyr204Phe, and Pro564Leu and for PAI-1 -675 4G/5G
was performed m a population-based case-control study of 42 white women aged <45 years with nonfatal hemorrhagic
stroke and 345 demographically similar control subjects
Results—Compared with the respective homozygous wild-type genotypes, the Tyr204/Phe204 genotypes (age-adjusted
odds raüo [OR] 2 9, 95% 95% CI l l to 7 5) and the Leu564/Leu564 genotype (OR 4 3, 95% CI l 4 to 13 7) were each
associated with an increased nsk of nonfatal hemorrhagic stroke The nsk estimate associated with the Phe204 vanant
was highest m women with subarachnoid hemorrhage and m nonsmokers, whereas the nsk estimate of the
Leu564/Leu564 genotype was highest m women with mtracerebral hemorrhage and in smokers Women who carried
either the Phe204 allele or the Leu564/Leu564 genotype m combmation with the PAI-1 5G/5G genotype had a nearly
20-fold increased risk of hemorrhagic stroke (OR 18 9, 95% CI 3 8 to 95 1)
Conduslons—Our findmgs suggest that the Phe204 and Leu564 variants of coagulation factor XIII may be markers for
genetic susceptibility to hemorrhagic stroke m women aged <45 years (Stroke. 2001;32:2580-2587.)
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H emorrhagic stroke occurs when an artery ruptures andcauses blood leakage mto the bram parenchyma or the
subarachnoid space Overall, it accounts for «20% of stroke
victims and is the most common form of stroke among young
adults Data from family studies have suggested the impor-
tance of genetic mfluence m hemorrhagic stroke, particularly
subarachnoid hemorrhage (SAH) '~3 However, the specific
genetic factors are pooily defmed4 Because mtracramal
aneurysms are associated with rare mhented connective
tissue disorders, most previous candidate gene studies have
focused on structural vessel wall protems, such collagen, or,
m the case of mtracerebral hemorrhage (ICH), cerebral
amyloid deposition 4 5
The events required for a hemorrhagic stroke to become
clmically manifest mclude not only the formation of a
weakened or abnormal vessel wall but also vessel rupture and
hemorrhage Inhented deficiency of coagulation factor XIII is
See Editorial Comment, page 2586
a very rare autosomal-recessive bleedmg disorder character-
ized by a particularly high rate of mtracramal hemorrhage (up
to 30% of cases)6 Coagulation factor XIII is a proenzyme
that circulates äs a heterotetramer composed of 2 catalytic
subumts (factor XIII subunit A [factor XIIIA]) and 2 carrier
subunits (factor XII subunit B [factor XIIIB]) Durmg the
final stages of coagulation, thrombm cleavage of factor XIIIA
results m formation of activated factor XIII, a transglutami-
nase that cross-lmks adjacent fibrm molecules to increase clot
stabihty and resistance to fibnnolysis Factor XIII also
participates m extracellular matrix remodelmg, cell adhesion
and migration, and tissue repair 7 In a rat model of expen-
mental cerebral aneurysm formation, exogenous admimstra-
tion of factor XIII abrogated the defective mtimal prolifera-
tive response to arterial wall mjury 8 Thus, deficiency of
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TABLE 1. Genotyping Assays for Factor XIII and PAI-1 Polymorphisms
Polymorphism














192 bp (161, 31)
113 bp (91, 22)
116 bp (95, 21)







Primer sequences are listed from 5' to 3', and the upper sequence represents the forward primer, the Iower
sequence, the reverse primer The underlmed bases were changed from the native sequence to mtroduce a restriction
enzyme recognition sequence that would result m digestion of the PCR product to the fragments shown m parentheses
for 1 (le, Leu34, Tyr204, Leu564, or 4G) of the 2 alleles Genomic DNA (50 ng) was amplified m a Standard 20-μΙ
PCR reaction for 35 cycles of denaturation at 94°C for 30 seconds, annealmg at 50°C for 30 seconds, and extension
at 72°C for 60 seconds, followed by a final extension at 72°C for 5 mmutes Aliquots of the PCR products were
digested with the appropnate restriction enzyme for 1 hour accordmg to the manufacturer's mstructions (New England
ßiolabs)
coagulation factor XIII may contnbute to the occurrence of
hemorrhagic stroke through direct effects on vessel wall
mtegnty or aneurysm formation m addition to bleedmg
tendency
A common factor XIIIA gene nucleotide Substitution
(polymorphism) results m a Val34Leu ammo acid Substitu-
tion and was recently associated with mcreased nsk of
pnmary ICH m a predommantly elderly patient population 9
Two other common factor XIIIA polymorphisms, Tyr204Phe
and Pro564Leu, have been associated with decreased plasma
factor XIII levels,10—l2 but their roles m hemorrhagic stroke
have not been previously assessed Therefore, we exammed
the association of the factor XIII Val34Leu, Tyr204Phe, and
Pro564Leu polymorphisms with hemorrhagic stroke by usmg
samples from a population-based case-control study of
women aged <45 years Plasminogen activator mhibitor-1
(PAI-1) is a major Inhibitor of fibrmolysis and, hke factor
XIII, is involved m fibnn stabilization, vascular remodelmg,
and tissue repair 13 The PAI-1 —675 4G/5G promoter poly-
morphism has been associated with Variation m plasma PAI-1
levels14 and with the nsk of early-onset stroke'5 or cerebro-
vascular mortality m women 16 Thus, we additionally as-
sessed potential gene-gene mteractions between the PAI-1
4G/5G polymorphism and the factor XIII polymorphisms
Subjects and Methods
Study Subjects and Data Collection
The source population for the present study was women aged 18 to
44 years residmg m 3 contiguous counties m western Washington
state between 1991 and 1995 and represented «*2 2 milhon women-
years at nsk 17 18 Ehgible stroke patients free of pnor cerebrovascular
disease were imtially identified by chart review of discharge diag-
noses from all 34 Hospitals and Emergency Medical Service mcident
reports in the study region Stroke was defmed äs evidence of new
focal neurological deficit(s) with no other apparent cause (le, bram
tumor, infection, subdural hematoma, seizure, or other neurological
condition) lasting >24 hours On the basis of reviews of hospital
records, bram imagmg studies, and lumbar puncture results, 141 of
the 249 ehgible stroke cases were classified äs hemorrhagic by the
study neurologist (W T L ) Of the 141 hemorrhagic strokes, 91 were
further charactenzed äs SAH on the basis of either (1) blood within
the subarachnoid space m the presence or absence of a demonstrated
aneurysm and no evidence of artenovenous malformation or (2) an
aneurysm with blood in other locations (eg, the parenchyma or
ventncles) and no evidence of artenovenous malformation For the
remaimng 50 women, the strokes were classified äs ICH Six
hundred eighty-four control women aged 18 to 44 years without
history of cerebrovascular disease were identified from the same
geographic area and were frequency-matched to the age distnbution
of the cases
Of the 141 identified hemorrhagic stroke cases, 102 were ahve and
not disabled at the time of recruitment Eighty (78 4%) of the 102
patients with nonfatal hemorrhagic stroke and 526 (76 9%) of the
684 ehgible control subjects agreed to an m-person interview
Demographic charactenstics and medical histones were ascertamed
durmg the interview, and blood samples for DNA Isolation were
collected from 54 hemorrhagic stroke cases (37 SAH and 17 ICH)
and from 391 control subjects Case blood samples were obtamed at
least 3 months after the stroke (mean 8 months) All study subjects
gave informed consent accordmg to a protocol approved by the
Umversity of Washington human subjects committee and participat-
mg local hospitals Data collection for the present study did not
include Information regardmg the use of ephedra compounds
Factor XIII and PAI-1 Genotyping
Genomic DNA samples were prepared äs descnbed previously ls
Genotyping for the factor XIII Val34Leu polymorphism was pei-
formed by polymerase cham reaction (PCR) amphfication of
genomic DNA followed by restriction enzyme digestion (PCR-
RFLP) with Ddel '9 Similar PCR-RFLP genotypmg methods were
developed for the Tyr204Phe and Pro564Leu factor XIII and PAI-1
4G/5G polymorphisms, äs shown m Table l For all PCR amphfi-
cations, positive control DNA samples of known genotype äs well äs
a negative control without template DNA were mcluded Ten percent
of the study samples underwent repeat genotypmg analysis, and the
initial results were confirmed in all cases As an additional validation
measure, direct nucleotide sequencmg of the PCR products was
performed for selected homozygous or heterozygous mdividuals, m
every case, the sequencmg results agreed with the PCR-RFLP
genotypmg result
Statistical Analysis
Factor XIII allele frequencies weie calculated by gene counting
Genotype distnbutions and allele frequencies of each factor XIII
polymorphism were compared among different groups by the χ2 lest
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Το assess the relationship between the inhentance of allehc vanants
at one polymorphic locus and the allehc vanants at a second
polymorphic locus, pairwise Imkage disequihbiium between factor
XIII polymorphic loci was determmed among controls by usmg a
permutation proceduie of the expectation-maxirmzation algonthm20
and expressed äs D', which ranges fiom 0 (complete Imkage
equihbnum) to l (complete Imkage disequihbrmm) D' is reportedas
positive when the mmor allele at one polymorphic locus is associated
with the mmor allele at the other locus and is leported äs negative
when the mmor allele at one locus is associated with the major allele
at the other locus
The association of factor XIII genotype with hemorrhagic stroke
was exammed by unconditional logistic regiession adjusted for age
and was expressed äs odds ratlos (ORs) and 95% CIs Homozygosity
for the more common allele (le, Val34/Val34, Tyr204/Tyr204, or
Pio564/Pro564) was used äs the refeience group m the regression
models In the case of the Val34Leu and Pro564Leu polymorphisms,
2 dummy variables lepresentmg the heterozygous and rare homozy-
gous genotypes were modeled to provide separate estimates of
association for each genotype We also performed a multivanate
logistic regression model that included all 3 factor XIII poly-
morphisms simultaneously to adjust for the potential confoundmg
effects of the 2 remaming polymorphisms Because the present study
was exploratory m nature, in some mstances we exammed the
combmed nsk estimate associated with the presence of heterozygos-
ity for Phe204 or homozygosity for Leu564 on the basis of post hoc
analysis of our data
The extent to which associations with factor XIII genotypes were
modified by other putative stroke nsk factors was assessed through
analyses stratified by these other nsk factors To lest for the presence
of mteraction, multiphcative terms were mtroduced mto the logistic
regiession models, and the P value was computed for the hkelihood
ratio test by companng the model containmg the mteraction term
with the model lackmg the mteraction term Logistic regiession
models were peiformed by usmg Stata (version 6 O),21 and genetic
data analysis was performed by usmg Arlequm (version 2 000)22 All
statistical testing was 2-sided and perfoimed at the a=0 05 level
Analysis of Factor XIII Alleles Among Healthy
Black Subjects
Of the 54 hemorrhagic stroke cases and 391 control subjects with
analyzable DNA, race was self-reported m 12 cases and 46 controls
äs nonwhite (le, black, Asian, American Indian, or Hispamc) Black
women constituted only 5 of the hemoirhagic stroke cases and only
9 of the controls Therefoie, factor XIII allele frequencies among the
black population of Seattle were deteimmed by usmg a larger
number of blood samples obtamed from 124 healthy black blood
donors from the Füget Sound Blood Center Compared with the 345
white control subjects from our case-contiol study, the Leu34 (13%
versus 26%, P<0 001), Phe204 (0 4% versus 3 0%, P=0 02), and
Leu564 (15% versus 20%, P=005) alleles were significantly less
common among the 124 healthy blacks Because of these differences
in inteiracial factoi XIII allele frequencies, we excluded the 12
nonwhite hemorrhagic stroke cases and 46 nonwhite control subjects
from the present association study to mimmize the possibility of
confoundmg due to population admixture Therefore, our present
analysis of the relationship between factor XIII genotypes and nsk of
hemorrhagic stroke was restncted to the white study subjects with
DNA samples (42 hemoirhagic stroke cases and 345 controls)
Results
Characteristics of the Study Subjects
The charactenstics of the hemorrhagic stroke cases and
controls are summanzed in Table 2 The mean age was 37 8
years The overwhelmmg majority of the study participants
were premenopausal and not usmg oral contraceptives Cig-
arette smokmg and hypertension were more commonly re-
ported among hemorrhagic stroke cases than among the
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control subjects Of the 42 hemorrhagic stroke cases, 30 were
classified äs SAH, and 12 were classified äs ICH Intracramal
aneurysms were documented by imagmg studies m 23 (77%)
of the 30 women with SAH Artenovenous malformations
were documented m 4 (33%) of the 12 women with ICH In
the remaming 15 hemorrhagic stroke patients, no vascular
source could be identified
Factor XIII Genotypes, Alleles, and
Linkage Disequüibrium
The observed genotype distnbutions of the factor XIII
Val34Leu, Tyr204Phe, and Pro564Leu polymorphisms and
the calculated allele frequencies among the white subjects are
shown m Table 3 The genotype distnbutions of all 3 factor
XIII polymorphisms were m Hardy-Weinberg equilibnum
among the control subjects, mdicatmg the expected relation-
ship between genotype frequencies and calculated fiequen-
cies among our study population
Among the white control subjects, there was a tendency
toward negative Imkage disequihbnum between the
Val34Leu and Tyr204Phe polymorphisms (D'= -058,
P=0 17) and between the Val34Leu and Pro564Leu poly-
morphisms (D' = — 0 19, P=0 33) and a tendency toward
positive Imkage disequilibnum between the Tyr204Phe and
Pro564Leu polymorphisms (D' = +024, P=0 16) Among
the 124 black subjects, the negative Imkage disequihbnum
between Val34Leu and Pro564Leu was considerably strenger
(D' = -099, P=002)
Association of Factor XIII Polymorphisms With
Hemorrhagic Stroke
The genotype distnbutions and allele frequencies of the
Tyr204Phe and Pro564Leu polymorphisms differed signifi-
cantly among the hemorrhagic stroke cases and the control
subjects (Table 3) The age-adjusted OR associated with
bemg a camer of the Tyr204/Phe204 genotype was 2 9 (95%
CI 114 to 75) There was a 4-fold increased nsk of
hemorrhagic stroke associated with carrymg 2 copies of the
Leu564 allele (age-adjusted OR 4 3, 95% CI l 4 to 13 7) and
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TABLE 3. Factor XIII Genotypes in Hemorrhagic Stroke Gases and Controls
Val34Leu
Control subjects (n =345)
Hemorrhagic stroke patients
Tyr204Phe








*P value for χ2 test of homogeneity







































































(le VaI34/Val34, Tyr204/Tyr204 or Pro564/Pro564)
a moderately mcreased nsk associated with carrymg l copy
of the Leu564 allele (age-adjusted OR l 7, 95% Cl 0 9 to 3 4)
compared with the Pro564/Pro564 genotype For subjects
who camed at least l copy of the Leu564 allele and/or were
heterozygous for Tyr204/Phe204 (62% of cases versus 40%
of controls), the age-adjusted OR for hemorrhagic stroke was
2 6 (95% Cl l 3 to 5 0) The combmed prevalence of the
Tyr204/Phe204 genotype and/or the Leu564/Leu564 geno-
type was 26 2% among the hemorrhagic stroke cases com-
pared 9 3% of the controls (l case and l control carned both
genotypes) Thus, women carrymg either factor XIII geno-
type had a 3-fold mcreased nsk of hemorrhagic stroke
(age-adjusted OR 3 3, 95% Cl l 5 to 7 1) In contrast, the
presence of l or 2 copies of the Val34Leu polymorphism was
associated with a decreased nsk of hemorrhagic stroke
(age-adjusted OR «=0 7), but the CIs were compatible with
the absence of an association (Table 3)
We also assessed whether the associations between each
factor XIII polymorphism and hemorrhagic stroke were
influenced by the 2 remaimng factor XIII polymorphisms
with the use of multivanate adjustment For each factor XIII
polymorphism, adjustment for the other 2 did not appreciably
affect the umvanate nsk estimates in Table 3 (data not
shown)
For all 3 factor XIII polymorphisms, restnctmg the analy-
sis to the women who were either premenopausal or were not
usmg oral contraceptives did not appreciably alter the nsk
estimates for hemorrhagic stroke When they were analyzed
according to hemorrhagic stroke subtype, all 7 hemorrhagic
stroke cases carrymg the Phe204 allele belonged to the
subgroup of 30 women classified with SAH Thus, the factor
XIII Phe204 variant was associated with a nearly 5-fold risk
of SAH (age-adjusted OR 4 5, 95% Cl l 7 to 11 8) In
contrast, 10 (83%) of the 12 women with ICH camed at least
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0 9 (0 2-5 5)
2 8 (0 95-8 3)
25(04-189)
41 (1 3-128)
1 8 (0 3-9 5)
2 0 (0 6-6 6)
128(16-800)
Cases (n =42)












































5 6 (1 3-23 9)
36(1 04-121)
4 7 (0 3-87 8)
50(14-182)
2 0 (0 2-23 6)







Υ mdicates tyrosme, F, phenylalanme P, prohne, and L, leucme
*P value for mteraction
tOR and 95% Cl calculated for Leu564/Leu564 genotype compared with Pro564/Pro564+Pro564/Leu564 genotypes and adjusted for age
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l copy of the Leu564 allele compared with only 127 (37%) of
the 345 controls (age-adjusted OR 9 l, 95% CI l 9 to 42 8)
The nsk of hemorrhag:c stroke associated with Phe204 and
Leu564/Leu564 was modified by current cigarette smokmg
The association with the Phe204 vanant was largest among
nonsmokers, whereas the effect of the Leu564/Leu564 geno-
type was most pronounced among smokers (Table 4) The
nsk of hemorrhagic stroke associated with either the Phe204
vanant or the Leu564/Leu564 genotype was also particularly
high among the subgroup of women with the PAI-1 5G/5G
genotype Among the subgroup of women who carned the
PAI-1 5G/5G genotype, the presence of either the Phe204
allele or the Leu564/Leu564 genotype was associated with a
nearly 20-fold mcreased nsk of hemorrhagic stroke (age-
adjusted OR 18 9, 95% CI 3 8 to 95 1) By contrast, there was
no mcreased nsk of hemorrhagic stroke in women with either
factor XIII genotype who camed the PAI-1 4G/4G or 4G/5G
genotype (age-adjusted OR l l, 95% CI 0 6 to 4 6) This
resulted in a P value for mteraction of 0 016
Discussion
Our findmgs from a population-based association study
among young white women mdicate that 2 common genetic
vanants of coagulation factor XIIIA, Phe204 and Leu564, are
each associated with a 3- to 4-fold mcreased nsk of nonfatal
hemorrhagic stroke Although the 2 mtragenic factor XIII
polymorphisms were m partial hnkage disequilibnum, the
associations with stroke were mutually mdependent The
Leu564 allele has been associated with decreased plasma
factor XIII levels,1011 and the Phe204 vanant has been
associated with reduced specific activity of plasma factor
XIII12 Decreased clot stability may lead to greater suscepti-
bihty to mtracramal hemorrhage, particularly among younger
individuals, who tend to have lower factor XIII levels 23
The nsk estimates associated with the 2 factor XIII
polymorphisms appeared to be modified by cigarette smok-
mg, although m opposite directions The risk associated with
the Phe204 vanant was greatest among nonsmokers, whereas
the effect of the Leu564/Leu564 genotype was most pro-
nounced among smokers There was also a Suggestion that the
nsk associated with the Phe204 vanant was highest among
the women with SAH, whereas the risk associated with the
Leu564/Leu564 genotype was most pronounced among the
women with ICH Cigarette smokmg has been shown to
mcrease the nsk of rupture and hemorrhage m subjects with
mtracramal aneurysm 24 25 However, cigarette smokmg is also
associated with mcreased plasma factor XIII levels23 äs well
äs decreased fibrmolysis 26 Thus, our findmgs suggest that the
detnmental effect on clot or vessel wall stability associated
with the Phe204 vanant may be "neutrahzed" in cigarette
smokers
The risk estimate associated with the presence of either the
Tyr204/Phe204 or Leu564/Leu564 genotype was particularly
large among women carrymg the PAI-1 promoter 5G/5G
genotype PAI-1 is a major physiological mhibitor of fibn-
nolysis, and the 5G/5G genotype has been associated with
decreased plasma levels of PAI-1 relative to the 4G/4G
genotype 14 Thus, the reduced clotting activity associated
with the Phe204 and Leu564 factor XIII vanants may be
compounded by mcreased fibrmolysis associated with PAI-1
5G/5G, which potentially mcreases the hkehhood of mtracra-
mal hemorrhage In addition, factor XIII and PAI-1 both may
participate in vascular remodelmg, tissue repair, and angio-
genesis 713 27 28 Delayed wound heahng, mtracramal hemor-
rhage, and recurrent miscamage are common features of
mhented factor XIII deficiency,6 and an mcreased prevalence
of the factor XIII Phe204 allele was recently noted among
women with recurrent miscamage '' Thus, genetic Variation
of factor XIII may affect the occurrence of hemorrhagic
stroke through effects on vessel wall stability and aneurysm
formation or rupture, äs well äs decreased clot stability
ICH and SAH are both more common among blacks than
whites, and ICH is particularly prevalent in Asian popula-
tions It is interestmg to note that the Leu564 allele (which
our data suggest may be more strongly related to ICH) is
more common among Japanese than white individuals29
Because our data mdicate that both the Phe204 and Leu564
alleles are less common among blacks than whites, there must
be other genetic or environmental determmants responsible
for the mcreased mcidence of hemorrhagic stroke among
blacks
The lack of association between the factor XIII Val34Leu
polymorphism and risk of hemorrhagic stroke m the present
study contrasts with the association reported among elderly
Bntish patients with ICH 9 However, it should be noted that
our patient population was considerably younger and that
most of the strokes were due to SAH rather than ICH Thus,
it is possible that the Val34Leu mutation is more strongly
related to ICH than SAH However, another recently pub-
hshed study involving a larger number of subjects with both
hemorrhagic stroke subtypes did not find any association
between the Val34Leu genotype and the risk of hemorrhagic
stroke 30
Several limitations of the present study should be noted
Because hemorrhagic stroke is an uncommon event in women
aged <45 years, the number of cases m the present study is
small, which may mcrease the hkehhood of a spunous
association The analysis of multiple subgroups also mcreases
the possibihty of a false-positive association, therefore, the
findmgs with respect to mteraction between factor XIII and
other risk factors should be mterpreted cautiously The
infrequency of hemorrhagic stroke in young women also
precluded the use of a prospective design to lest our hypoth-
eses Thus, we were able to study only women who survived
at least 3 months after their strokes Because hemorrhagic
stroke is associated with a high case-fatahty rate (26% in the
present study), our results may be biased because of the
exclusion of fatal cases if a particular factor XIII vanant is
associated with fatal outcome rather than occurrence of
hemorrhagic stroke Fmally, although we hmited our analysis
to white subjects, we cannot exclude the possibihty of a
spunous association arising that is due to population
admixture
Another potential hrmtation of the present study is that
citrated plasma samples were not available for measurement
of factor XIII clotting activity levels among the study
subjects However, even if such plasma samples had been
collected, the retrospective study design might complicate
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Interpretation of factor XIII levels among the stroke cases
measured after the acute event Because previous studies have
demonstrated a relationship between the factor XIII
Tyr204Phe and Pro564Leu polymorphisms and plasma factor
XIII levels,10-12 the determmation of factor XIII genotype
actually may be preferable to the measurement of factor XIII
activity levels m th:s settmg The advantage of studymg
genetic vanants is that they are "fixed at birth" and, therefore,
clearly precede disease onset and are not confounded by
fluctuations in plasma activity levels related to the acute
cerebrovascular event or by other behavioral and environ-
mental nsk factors that mfluence factor XIII activity levels 23
In summary, genetic Variation of coagulation factor XIII may
be important m the occurrence of hemorrhagic stroke m young
white women, particularly m combmation with other genetic and
environmental nsk factors These fmdings require confirmation
in larger studies, which should mclude fatal and nonfatal
hemorrhagic stroke cases, other ethnic groups, and family-based
studies that assess genetic hnkage äs well äs association
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Editorial Comment
Hematology-Neurology Connection: Association Between Factor XIII and
Hemorrhagic Stroke in Young Women Through Genetic Polymorphism
Coagulation factor XIII (FXIII) belongs to the enzyme family
of transglutammases that catalyze the formation of covalent
e-(7-glutamyl)lysme (amide) bonds on cross-lmked protems '
Protein cross-lmkmg is mvolved m several physiological
processes, mcludmg hemostasis, wound healmg, and tumor
growth FXIII is a proenzyme that is activated by thrombm
dunng the late stage of blood coagulation It is a heterotet-
ramer consistmg of 2 catalytic A (FXIIIA) and 2 noncatalytic
B (FXIIIB) subunits On thrombin activation, the enzyme (le,
activated FXIII) catalyzes the formation of covalent bonds
among fibrm monomers Activated FXIII also promotes clot
retraction2 by bmdmg to platelet GPIIb/IIIa receptors (at-
tached to platelet microskeleton via its cytoplasmic domain)
and cross-links fibrm with a number of other protems,
mcludmg fibronectm and a2-antiplasmin The end result is the
formation of sturdier thrombi, more resistant to shear- and
fibnnolysis-induced lysis These actions of activated FXIII
explam m part why older thrombi are more difficult to lyse
with thrombolytic agents FXIII has a long plasma half-hfe of
6 to 10 days, and hmited amounts are reqmred for normal
hemostasis (0 05 U/mL) Congemtal FXIII deficiency is
exceedmgly rare It is inhented äs an autosomal recessive trait
and caused by absence of either subunit Deficiency of the
FXIIIA subunit is the most common, however Homozygotes
have a lifelong bleedmg diathesis, typically starting with
bleeding from the umbilical cord at birth and later character-
ized by delayed bleedmg after trauma or surgery and delayed
wound bleeding Dunng childhood, patients bruise easily and
expenence subcutaneous and mtramuscular hematomas
Spontaneous abortion has been reported in affected females,
presumably owmg to defective formation of a cytotropho-
blastic shell 3 Hemorrhage into the central nervous System
occurs more frequently than with other inhented coagulation
defects Other conditions mvolvmg defective fibrm formation
(eg, dissemmated intravascular coagulation) or fibrm break-
down (eg, thrombolytic admimstration) are also associated
with central nervous System bleeding These observations
suggest the theme that faulty fibrm formation or fibrm
breakdown is associated with central nervous System bleed-
ing Most cases of congemtal FXIII deficiency are due to
mutations m the subunit A gene, often mvolvmg pomt
mutations causmg ammo acid Substitution In addition, sev-
eral smgle nucleotide polymorphisms of the FXIIIA gene
resultmg m smgle ammo acid substitutions have been de-
scnbed Genetic polymorphisms are typically encountered m
at least 1% of the normal population The dissection of human
disease through genetic polymorphisms has become an im-
portant research area of vascular biology and other disciplmes
m recent years
In the precedmg article, Reiner et al exammed the associ-
ation between the Val34Leu, Tyr204Phe, and Pro564Leu
variants of FXIIIA and the nsk of nonfatal hemorrhagic
stroke m young women by conductmg a population-based
case-control study They also exammed possible gene-gene
mteractions between FXIIIA polymorphisms and the 4G/5G
Promoter polymorphism of the PAI-1 gene P AI-1 is the mam
mhibitor of tissue plasmmogen activator and is released from
activated endothehal cells and the α-granules of activated
platelets The mam results show that women carrymg the
Tyr204/Phe204 or Leu564/Leu564 genotype have a sigmfi-
cantly higher nsk of hemorrhagic stroke compared with
control subjects (age-adjusted ORs of 2 9 and 4 3, respective-
ly) This nsk is further magnified when either genotype is
combmed with the PAI-1 5G/5G alleles (age-adjusted OR
189) The authors conclude that the Phe204 allele and
Leu564/Leu564 genotypes may be markers of genetic sus-
ceptibihty to nonfatal hemorrhagic stroke m young white
women
A number of aspects emergmg from this well-designed
study deserve mentiomng First, the mvestigators selected the
Tyr204Phe and Pro564Leu genotypes their phenotype asso-
ciated with decreased plasma FXIII levels This design
feature underscores the fundamental prmciple that for a gene
change to have an impact, it must be mediated through a
phenotype m turn associated with a clmical effect Studies of
association between polymorphisms and disease without
reference to phenotype may lead to false associations, influ-
enced by other extraneous factors Second, m contrast to
similar studies m older patients, the Leu34 allele is not
associated with an increased hemorrhagic risk The authors
pomt out the Leu34 allele may be more closely related to the
nsk of mtracerebral bleeding than of subarachnoid hemor-
rhage, the most common type encountered m their study of
younger women Other case-control studies45 m ischemic
bram syndromes and m myocardial infarction have yielded
negative associations between FXIIIA-Leu34 and these dis-
ease outcomes Recent m vitro studies6 have shown that FXIII
contammg Leu34 is activated more rapidly by thrombin and
results m altered fibnn with reduced tensile strength Thirdly,
the gene-gene interaction observed between Tyr204/Phe204
or Leu564/Leu564 and PAI-1 5G/5G genotype (but not
4G/5G) is biologically plausible The PAI-1 4G/5G genotype
has been associated m some studies with increased PAI-1
activity m plasma (causmg reduced fibrinolysis) and in-
creased risk of myocardial infarction or ischemic stroke
Conversely, the PAI-1 5G/5G genotype has been associated
with reduced PAI-1 activity, possibly causmg increased
fibrinolytic activity Collectively, the current report and other
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studies raise the hypothesis that some FXIIIA polymorphisms
may be somewhat protective agamst thrombosis but are
perhaps mvolved m the pathogenesis of hemorrhagic disor-
ders These prehmmary findmgs will need to be mvestigated
further m future studies
In view of their widespread availability, molecular biology
techniques have now entered the clmical tnal arena Studies
of genetic polymorphisms abound m practically all disci-
plmes of clmical research The underlymg prmciple is based
on the notion that phenotypic vanations among mdividuals,
includmg anthropometncs, disease susceptibihty, and re-
sponse to the environment, are mostly due to naturally
occumng vanations in DNA sequence, consistmg of smgle
nucleotide polymoφhlsms (SNPs) SNPs are evenly distnb-
uted throughout the genome and thus likely flank or are
nearby codmg genes 7 Association studies examme whether
polymoφhlc alleles occur more frequently m cases than m
controls If a sigmficant association occurs, either the poly-
morphism is closely associated with the susceptibihty locus
or is m hnkage disequihbnum However, these associations
do not necessanly imply a causality link with the disease
under study and, like any other case-control study, are
susceptible to bias The genetic markers identified through
studies must be viewed äs nsk factors, albeit at the molecular
level Two advantages of genetic markers over epidermolog-
ical nsk factors or biochemical markers are that their expo-
sure always precedes the disease of mterest and the underly-
mg disease cannot influence test results These 2 factors are
common sources of bias in classic case-control studies The
vahdity of polymorphisms äs genetic markers can be ascer-
tamed only through several studies showing consistent re-
sults Perhaps one of the best examples to cite was the
demonstration of the angiotensin-convertmg enzyme inser-
tion/deletion (I/D) polymorphism äs marker of susceptibihty
to cardiovascular disease
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